The SIGN guidelines say that both morphine sulphate immediate release and oral transmucosal fentanyl citrate are effective in reducing breakthrough cancer pain.1 But little evidence (and certainly not grade B evidence) supports the unlicensed use of oral morphine. Its pharmacodynamic profile also does not mirror the temporal characteristics of most episodes of breakthrough cancer pain. These are acute in onset, short in duration, and …